WealthShield Partners LLC Invests $213,000 in Eli Lilly and Company (NYSE:LLY)

WealthShield Partners LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) during the second quarter, HoldingsChannel reports. The institutional investor bought 658 shares of the company’s stock, valued at approximately $213,000.

Other institutional investors have also made changes to their positions in the company. Capital World Investors boosted its position in shares of Eli Lilly and by 17.0% in the first quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock valued at $6,402,838,000 after acquiring an additional 3,242,548 shares during the period. Jennison Associates LLC raised its stake in Eli Lilly and by 31.1% during the second quarter. Jennison Associates LLC now owns 10,358,066 shares of the company’s stock worth $3,358,396,000 after acquiring an additional 2,456,760 shares in the last quarter. Capital International Investors grew its holdings in shares of Eli Lilly and by 30.5% in the 1st quarter. Capital International Investors now owns 8,839,241 shares of the company’s stock worth $2,532,024,000 after purchasing an additional 2,063,557 shares during the last quarter. 1832 Asset Management L.P. lifted its holdings in Eli Lilly and by 2,999.1% during the 1st quarter. 1832 Asset Management L.P. now owns 1,621,696 shares of the company’s stock valued at $458,118,000 after purchasing an additional 1,569,368 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after acquiring an additional 1,219,424 shares in the last quarter. 82.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LLY shares. Wells Fargo & Company lifted their price target on Eli Lilly and from $305.00 to $365.00 and gave the company an “equal weight” rating in a report on Wednesday, November 2nd. Argus lifted their target price on Eli Lilly and from $315.00 to $360.00 in a research note on Friday, September 30th. Citigroup upped their price target on Eli Lilly and from $285.00 to $370.00 in a research note on Thursday, August 25th. The Goldman Sachs Group boosted their price objective on Eli Lilly and from $281.00 to $313.00 and gave the stock a “neutral” rating in a report on Tuesday, November 8th. Finally, Truist Financial increased their price objective on shares of Eli Lilly and from $400.00 to $421.00 in a report on Tuesday, November 15th. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $355.89.

Insider Activity

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 101,631 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $335.07, for a total value of $34,053,499.17. Following the completion of the transaction, the insider now owns 103,773,810 shares of the company’s stock, valued at approximately $34,771,490,516.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Alonzo Weems sold 656 shares of the company’s stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $326.23, for a total value of $214,006.88. Following the sale, the executive vice president now directly owns 6,950 shares in the company, valued at $2,267,298.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 101,631 shares of the company’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $335.07, for a total value of $34,053,499.17. Following the transaction, the insider now directly owns 103,773,810 shares in the company, valued at $34,771,490,516.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 571,297 shares of company stock worth $193,929,777. Insiders own 0.12% of the company’s stock.

Eli Lilly and Stock Performance

Eli Lilly and stock opened at $361.67 on Monday. The company has a quick ratio of 0.88, a current ratio of 1.13 and a debt-to-equity ratio of 1.39. The stock has a market cap of $343.65 billion, a PE ratio of 54.30, a P/E/G ratio of 2.28 and a beta of 0.36. Eli Lilly and Company has a 12-month low of $231.87 and a 12-month high of $369.80. The business’s 50-day moving average price is $335.81 and its two-hundred day moving average price is $320.01.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be issued a dividend of $0.98 per share. The ex-dividend date is Monday, November 14th. This represents a $3.92 annualized dividend and a dividend yield of 1.08%. Eli Lilly and’s dividend payout ratio (DPR) is presently 58.86%.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.